Company Overview
CVRx, Inc. operates as a commercial-stage medical device company dedicated to the development, manufacturing, and commercialization of neuromodulation solutions designed for patients suffering from cardiovascular diseases, with a geographic footprint spanning the United States, Germany, and international markets. The firm functions within the healthcare sector, specifically targeting the medical devices industry, which implies a focus on high-regulation environments requiring rigorous clinical validation and specialized engineering for implantable technologies such as the Barostim device. The company's current scale is defined by a market capitalization of $246.80M and an annual revenue of $56.65M, supported by an employee base of 223 individuals. These valuation and revenue figures indicate that the company maintains a mid-market profile, suggesting it is in a growth phase where capital allocation is heavily weighted toward product expansion and commercialization rather than mature profit generation.
Financial Health
The company reported revenue of $56.65M over the trailing twelve months, yet recorded a net income of $-53,306,000 and an EBITDA of $-50,509,000, revealing a significant gap between top-line generation and bottom-line profitability that points to substantial operating expenses or investment costs inherent to the commercial-stage phase. This negative free cash flow of $-23,787,500 indicates a current lack of financial flexibility from operations, meaning the company relies on external capital sources to fund its ongoing activities and research initiatives. The gross margin stands at 85.3%, reflecting high pricing power or low cost of goods sold relative to revenue, while the operating margin of -69.8% and profit margin of -94.1% demonstrate that overhead costs and non-operating expenses are eroding profitability significantly before reaching the net income line. In terms of balance sheet leverage, the company holds $75.71M in cash against $50.50M in debt, resulting in a debt-to-equity ratio of 128.43, which suggests a leveraged capital structure despite the cash buffer, as liabilities exceed equity holdings. Liquidity is robust, evidenced by a current ratio of 7.63, indicating that short-term assets vastly exceed short-term obligations and providing a wide safety margin against immediate liquidity pressures. However, the return on equity is -96.6% and the return on assets is -26.9%, metrics that reveal management has not yet generated positive returns on shareholder capital or total assets, a common characteristic for companies investing heavily in future product potential.
Valuation Assessment
Valuation metrics present a complex picture given the negative earnings, with a trailing P/E ratio listed as N/A and a forward P/E of -5.28, implying that the market is pricing in a trajectory where earnings are not yet positive or are expected to remain negative in the near term. The price-to-book ratio is 6.27, indicating that the market values the company at more than six times its book value, which suggests a premium placed on the company's intangible assets, intellectual property, or future growth prospects rather than current tangible net worth. Alternative valuation measures such as the price-to-sales ratio of 4.36 and an EV/EBITDA of -4.39 further highlight that the stock is being valued based on revenue multiples and enterprise value relative to negative earnings, typical for biotech or medtech firms in development. The stock has traded between a 52-week high of $13.34 and a 52-week low of $4.30, meaning the current price sits within this volatility range, though the specific percentage distance from the high or low fluctuates with daily trading without a fixed current price provided in the data. With a beta of 1.24, the company exhibits price volatility that is greater than the broader market, suggesting that its stock price will likely experience larger swings in response to market movements or sector-specific news compared to the S&P 500.
Growth & Income
Revenue growth year-over-year is recorded at 4.4%, while earnings growth is listed as N/A, indicating that the company is still navigating the transition to profitability rather than demonstrating a mature pattern where earnings expand faster than revenue. Because the company has not established consistent positive earnings, there is no sustainable dividend yield or payout ratio to evaluate, as the firm currently retains all earnings to fund operations and development rather than distributing income to shareholders. This reinvestment strategy is standard for commercial-stage medical device companies that prioritize accelerating market penetration and R&D over providing immediate income yields to investors. Consequently, the overall growth and income profile is characterized by moderate top-line expansion without the support of a dividend, reflecting a capital-intensive business model where shareholder returns are expected to materialize through potential future profitability or strategic exits rather than regular payouts.